Alvarez Ralph, an insider at Eli Lilly and Co (LLY), purchased 55,163 shares of the company on November 16, 2025, at a price of $1,021.70 per share, bringing the total transaction value to $56.36 million. Following this transaction, Ralph holds a total of 55,163 shares in the company.
This transaction underscores the confidence that insiders may have in their company's future. Eli Lilly, a leader in the pharmaceuticals industry, is known for its diverse portfolio, including cardiometabolic health products like Humalog and Jardiance, as well as oncology and immunology treatments. The company, headquartered in Indianapolis, Indiana, has a market capitalization of $965.9 billion and a P/E ratio of 52.46.
While insider buying can be a positive signal, it is essential for investors to consider such transactions in context. Insider purchases are reported to the SEC, promoting transparency, but the motivations behind these trades can vary widely. Investors are encouraged to analyze patterns of insider activity over time, rather than relying solely on individual transactions.
Looking ahead, Eli Lilly is set to report earnings on April 28, 2026, with an expected EPS of $7.16 and revenue of $17.1 billion. This follows an anticipated EPS of $7.86 and revenue of $18.7 billion for the earnings report on August 4, 2026.